Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2017 09:15 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Name and Ticker Change Effective, Replay of Shareholder Conference Call Available

BEVERLY, Mass., June 09, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, Inc. (OTCQB:IPIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce that the Company’s name...
June 07, 2017 16:05 ET | Source: Cellceutix Corporation

Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc.

BEVERLY, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce to shareholders, and the public...
May 30, 2017 07:30 ET | Source: Cellceutix Corporation

Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting

BEVERLY, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to share further data supporting the p53 mechanism of action of Kevetrin and its...
May 18, 2017 09:30 ET | Source: Cellceutix Corporation

Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July

BEVERLY, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to announce that patient enrollment has been completed in the third and final cohort...
May 10, 2017 09:45 ET | Source: Cellceutix Corporation

Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude

BEVERLY, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
April 19, 2017 16:15 ET | Source: Cellceutix Corporation

Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations

BEVERLY, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology,...
April 10, 2017 07:30 ET | Source: Cellceutix Corporation

Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease

BEVERLY, Mass., April 10, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX), Accelerating Phase 2 trial for the Prevention of Severe Oral Mucositis (SOM)Annual Global Market for SOM may...
April 03, 2017 07:30 ET | Source: Cellceutix Corporation

Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors

BEVERLY, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to share further data supporting the p53 mechanism of action of Kevetrin in...
March 27, 2017 10:00 ET | Source: Cellceutix Corporation

Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment

BEVERLY, Mass., March 27, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), today presented positive results from the Company's ongoing randomized, double-blind Phase 2...
March 21, 2017 07:30 ET | Source: Cellceutix Corporation

Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease

BEVERLY, Mass., March 21, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...